膦甲酸钠治疗对患有巨细胞病毒性视网膜炎的艾滋病患者人类免疫缺陷病毒p24抗原水平的影响。

Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.

作者信息

Reddy M M, Grieco M H, McKinley G F, Causey D M, van der Horst C M, Parenti D M, Hooton T M, Davis R B, Jacobson M A

机构信息

AIDS Clinical Trials Unit, St. Luke's/Roosevelt Hospital Center, New York, NY 10019.

出版信息

J Infect Dis. 1992 Sep;166(3):607-10. doi: 10.1093/infdis/166.3.607.

DOI:10.1093/infdis/166.3.607

PMID:1323624

Abstract

Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials. The HIV p24 antigen levels decreased from a baseline value of 199 +/- 236 (mean +/- SD) and 140 pg/mL (median) to 106 +/- 218 and 28 pg/mL after 14 days of foscarnet induction therapy (60 mg/kg every 8 h). During chronic foscarnet maintenance, there was a sustained decrease in mean HIV p24 antigen levels below pre-foscarnet therapy baseline concentrations for a median of 16 weeks after foscarnet induction. These results provide evidence for a sustained clinical antiretroviral effect of chronic foscarnet maintenance therapy, consistent with a recent report that foscarnet-treated AIDS patients live longer than ganciclovir-treated patients.

摘要

在一项I/II期多中心试验中，对22例艾滋病患者进行了循环人类免疫缺陷病毒（HIV）p24抗原水平检测。这些患者在接受膦甲酸钠诱导和维持治疗以治疗巨细胞病毒性视网膜炎后，基线时血清抗原可检测到。HIV p24抗原水平从基线值199±236（平均值±标准差）和140 pg/mL（中位数）降至膦甲酸钠诱导治疗14天后（每8小时60 mg/kg）的106±218和28 pg/mL。在慢性膦甲酸钠维持治疗期间，膦甲酸钠诱导后平均HIV p24抗原水平持续下降至低于膦甲酸钠治疗前基线浓度，中位数为16周。这些结果为慢性膦甲酸钠维持治疗的持续临床抗逆转录病毒作用提供了证据，这与最近一份报告一致，该报告称接受膦甲酸钠治疗的艾滋病患者比接受更昔洛韦治疗的患者寿命更长。